SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment of Localized Pancreatic Cancer

Julia Button; Elishama Kanu; Ethan Agritelley; Erin M. Dickey; Brian Diskin; Akshat Sarkari; Unaiza Zaman; Rajalaxmi Sharanappa; Annie Kim; Vanessa Marin-Guerra; David G. Brauer; Jashodeep Datta; Brock Hewitt; Michael E. Lidsky; Emil Lou; Nipun Merchant; Daniel Nussbaum; Susanna Ulahannan; Caitlin Hester; Brett L. Ecker

Journal Article

SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment of Localized Pancreatic Cancer

Button J
Kanu E
Agritelley E
et al.

Annals of Surgery (2025)

DOI: 10.1097/sla.0000000000006966

N/ACitations

1Readers

Get full text

Cite

CITATION STYLE

APA

Button, J., Kanu, E., Agritelley, E., Dickey, E. M., Diskin, B., Sarkari, A., … Ecker, B. L. (2025). SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment of Localized Pancreatic Cancer. Annals of Surgery. https://doi.org/10.1097/sla.0000000000006966

SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment of Localized Pancreatic Cancer

Cite

Register to see more suggestions